Li Rongkang, Chen Wenkang, Lu Chong, Li Xinji, Chen Xuan, Huang Guocheng, Wen Zhenyu, Li Hang, Tao Lingzhi, Hu Yimin, Zhao Zhengping, Chen Zebo, Ni Liangchao, Lai Yongqing
Department of Urology, Guangdong and Shenzhen Key Laboratory of Reproductive Medicine and Genetics, Peking University Shenzhen Hospital, Clinical College of Anhui Medical University, Shenzhen, Guangdong, China.
The Fifth Clinical Medical College of Anhui Medical University, Hefei, Anhui, China.
Front Oncol. 2023 Jan 16;12:1076303. doi: 10.3389/fonc.2022.1076303. eCollection 2022.
Renal cell carcinoma (RCC) is one out of the most universal malignant tumors globally, and its incidence is increasing annually. MicroRNA (miRNA) in serum could be considered as a non-invasive detecting biomarker for RCC diagnosis.
A total of 224 participants (112 RCC patients (RCCs) and 112 normal controls (NCs)) were enrolled in the three-phrase study. Reverse transcription quantitative PCR (RT-qPCR) was applied to reveal the miRNA expression levels in RCCs and NCs. Receiver operating characteristic (ROC) curves and the area under the ROC curve (AUC) were utilized to predict the diagnostic ability of serum miRNAs for RCC. Bioinformatic analysis and survival analysis were also included in our study.
Compared to NCs, the expression degree of miR-155-5p, miR-224-5p in serum was significantly upregulated in RCC patients, and miR-1-3p, miR-124-3p, miR-129-5p, and miR-200b-3p were downregulated. A four-miRNA panel was construed, and the AUC of the panel was 0.903 (95% CI: 0.847-0.944; p < 0.001; sensitivity = 75.61%, specificity = 93.67%). Results from GEPIA database indicated that CHL1, MPP5, and SORT1 could be seen as promising target genes of the four-miRNA panel. Survival analysis of candidate miRNAs manifested that miR-155-5p was associated with the survival rate of RCC significantly.
The four-miRNA panel in serum has a great potential to be non-invasive biomarkers for RCC sift to check.
肾细胞癌（RCC）是全球最常见的恶性肿瘤之一，其发病率逐年上升。血清中的微小RNA（miRNA）可被视为用于RCC诊断的非侵入性检测生物标志物。
共有224名参与者（112例RCC患者（RCCs）和112名正常对照（NCs））纳入了这项三阶段研究。应用逆转录定量PCR（RT-qPCR）来揭示RCCs和NCs中miRNA的表达水平。利用受试者工作特征（ROC）曲线和ROC曲线下面积（AUC）来预测血清miRNA对RCC的诊断能力。我们的研究还包括生物信息学分析和生存分析。
与NCs相比，RCC患者血清中miR-155-5p、miR-224-5p的表达程度显著上调，而miR-1-3p、miR-124-3p、miR-129-5p和miR-200b-3p则下调。构建了一个四miRNA组合，该组合的AUC为0.903（95%CI：0.847-0.944；p<0.001；敏感性=75.61%，特异性=93.67%）。GEPIA数据库的结果表明，CHL1、MPP5和SORT1可被视为该四miRNA组合的有前景的靶基因。候选miRNA的生存分析表明，miR-155-5p与RCC的生存率显著相关。
血清中的四miRNA组合有很大潜力成为用于RCC筛查的非侵入性生物标志物。
